MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
<jats:p>Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma—namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies—may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, op...
| Main Authors: | , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Proceedings of the National Academy of Sciences
2023
|
| Online Access: | https://hdl.handle.net/1721.1/147778 |